BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16872715)

  • 1. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
    Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
    Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
    Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.
    Mizoguchi M; Betensky RA; Batchelor TT; Bernay DC; Louis DN; Nutt CL
    J Neuropathol Exp Neurol; 2006 Dec; 65(12):1181-8. PubMed ID: 17146292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
    Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells.
    Ghosh MK; Sharma P; Harbor PC; Rahaman SO; Haque SJ
    Oncogene; 2005 Nov; 24(49):7290-300. PubMed ID: 16007122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells.
    Su JC; Lin KL; Chien CM; Tseng CH; Chen YL; Chang LS; Lin SR
    Life Sci; 2010 Jan; 86(5-6):207-13. PubMed ID: 20036260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas.
    Ikeda S; Takabe K; Inagaki M; Funakoshi N; Suzuki K; Shibata T
    Pathol Int; 2007 May; 57(5):268-75. PubMed ID: 17493174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
    Conde E; Angulo B; Tang M; Morente M; Torres-Lanzas J; Lopez-Encuentra A; Lopez-Rios F; Sanchez-Cespedes M
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):710-7. PubMed ID: 16467080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors.
    Dobashi Y; Suzuki S; Sugawara H; Ooi A
    Hum Pathol; 2007 Jun; 38(6):914-25. PubMed ID: 17376509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L; Turkson J; Karras JG; Jove R; Haura EB
    Oncogene; 2003 Jul; 22(27):4150-65. PubMed ID: 12833138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
    Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
    Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.
    Chou YT; Lin HH; Lien YC; Wang YH; Hong CF; Kao YR; Lin SC; Chang YC; Lin SY; Chen SJ; Chen HC; Yeh SD; Wu CW
    Cancer Res; 2010 Nov; 70(21):8822-31. PubMed ID: 20978205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.
    Schiffer HH; Reding EC; Fuhs SR; Lu Q; Piu F; Wong S; Littler PL; Weiner DM; Keefe W; Tan PK; Nash NR; Knapp AE; Olsson R; Brann MR
    Mol Pharmacol; 2007 Feb; 71(2):508-18. PubMed ID: 16968809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
    Weng MS; Ho CT; Ho YS; Lin JK
    Toxicol Appl Pharmacol; 2007 Jan; 218(2):107-18. PubMed ID: 17182072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways.
    Park CM; Park MJ; Kwak HJ; Lee HC; Kim MS; Lee SH; Park IC; Rhee CH; Hong SI
    Cancer Res; 2006 Sep; 66(17):8511-9. PubMed ID: 16951163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
    Suehisa H; Toyooka S; Hotta K; Uchida A; Soh J; Fujiwara Y; Matsuo K; Ouchida M; Takata M; Kiura K; Date H
    J Clin Oncol; 2007 Sep; 25(25):3952-7. PubMed ID: 17761979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.
    López-Malpartida AV; Ludeña MD; Varela G; García Pichel J
    Lung Cancer; 2009 Jul; 65(1):25-33. PubMed ID: 19046792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
    Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
    Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.